NASDAQ:PLSE Pulse Biosciences (PLSE) Stock Price, News & Analysis $49.75 -0.75 (-1.49%) Closing price 04:00 PM EasternExtended Trading$49.84 +0.09 (+0.18%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Pulse Biosciences Stock (NASDAQ:PLSE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pulse Biosciences alerts:Sign Up Key Stats Today's Range$48.62▼$51.2650-Day Range$34.25▼$55.2052-Week Range$12.56▼$58.90Volume421,363 shsAverage Volume645,023 shsMarket Capitalization$3.52 billionP/E RatioN/ADividend YieldN/APrice Target$53.20Consensus RatingModerate Buy Company Overview Pulse Biosciences, Inc. is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue. The company’s lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology. Pulse Biosciences is also advancing applications in areas including cardiac surgery, cardiac ablation and oncology, although several of these programs remain investigational and subject to regulatory review. Founded in 2009 and headquartered in Hayward, California, Pulse Biosciences serves the medical technology and healthcare markets primarily through its development of physician-focused systems and disposable treatment accessories. The company is led by President and Chief Executive Officer Burke T. Barrett. Its products and development programs are directed toward clinicians and healthcare providers in the United States and other international markets where applicable regulatory clearances have been obtained.AI Generated. May Contain Errors. Read More Pulse Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScorePLSE MarketRank™: Pulse Biosciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 646th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingModerate Buy Consensus RatingPulse Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Pulse Biosciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoveragePulse Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pulse Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pulse Biosciences are expected to decrease in the coming year, from ($1.29) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulse Biosciences is -42.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulse Biosciences is -42.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulse Biosciences has a P/B Ratio of 41.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pulse Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.06% of the float of Pulse Biosciences has been sold short.Short Interest Ratio / Days to CoverPulse Biosciences has a short interest ratio ("days to cover") of 3.89, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulse Biosciences has recently increased by 0.59%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPulse Biosciences does not currently pay a dividend.Dividend GrowthPulse Biosciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.71 News SentimentPulse Biosciences has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Pulse Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for PLSE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Pulse Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $199,931.00 in company stock, which represents 0.0057% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Pulse Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $199,931.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders74.00% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.95% of the stock of Pulse Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pulse Biosciences' insider trading history. Receive PLSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLSE Stock News HeadlinesPulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Target Price of $50.20October 6 at 6:15 AM | americanbankingnews.comPulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA DataOctober 3 at 7:10 PM | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 6 at 1:00 AM | Profits Run (Ad)Pulse Biosciences: Promising Technology, But Hard To Justify Its ValuationSeptember 27, 2026 | seekingalpha.comPulse Biosciences (NASDAQ:PLSE) Research Coverage Started at BTIG ResearchSeptember 26, 2026 | americanbankingnews.comPulse Biosciences Completes Enrollment in 100-Patient Thyroid Nodule StudySeptember 16, 2026 | finance.yahoo.comPulse Biosciences consensus price target increased 12.27% to $51.82September 16, 2026 | msn.comPulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid NodulesSeptember 15, 2026 | finance.yahoo.comSee More Headlines PLSE Stock Analysis - Frequently Asked Questions How have PLSE shares performed this year? Pulse Biosciences' stock was trading at $13.73 on January 1st, 2026. Since then, PLSE shares have increased by 262.3% and is now trading at $49.75. How were Pulse Biosciences' earnings last quarter? Pulse Biosciences, Inc (NASDAQ:PLSE) posted its earnings results on Thursday, August, 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.07. The company had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative trailing twelve-month return on equity of 94.42%. Read the conference call transcript. When did Pulse Biosciences IPO? Pulse Biosciences (PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO. How do I buy shares of Pulse Biosciences? Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pulse Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pulse Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and Jabil (JBL). Company Calendar Last Earnings8/06/2026Today10/06/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PLSE's financial health is in the Green zone, according to TradeSmith. PLSE has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PLSE CIK1625101 Webwww.pulsebiosciences.com Phone(510) 906-4600FaxN/AEmployees116Year Founded2014Price Target and Rating Average Price Target for Pulse Biosciences$53.20 High Price Target$70.00 Low Price Target$35.00 Potential Upside/Downside+6.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$72.78 million Net Margins-6,755.78% Pretax Margin-6,755.78% Return on Equity-94.42% Return on Assets-79.96% Debt Debt-to-Equity RatioN/A Current Ratio9.63 Quick Ratio9.61 Sales & Book Value Annual Sales$350 thousand Price / Sales10,063.71 Cash FlowN/A Price / Cash FlowN/A Book Value$1.19 per share Price / Book41.81Miscellaneous Outstanding Shares70,800,000Free Float18,408,000Market Cap$3.52 billion OptionableOptionable Beta1.57 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:PLSE) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulse Biosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulse Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
